Evaluation of the Predictive Value of Microemboli Detected by Robotic Transcranial Doppler for the Occurrence of an Acute Ischemic Stroke or Left Ventricular Thrombus in STEMI Patients With Left Ventricular Dysfunction (EMAIL)

November 6, 2026 updated by: CHC Montlegia

The goal of this study is to define a correlation between the number of microembolic signals (MES) detected and the risk of occurrence of an Acute Ischemic Stroke (AIS) at 2 years or a Left Ventricular Thrombus (LVT) at 6 weeks Participants will perform a transcranial doppler with MES detection.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

116

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Sarah Miceli, Master in Biomedical Sciences
  • Phone Number: 00 4 93 27 28 63
  • Email: sarah.miceli02@chc.be

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patient aged 18 or over
  • Patient with proven post-STEMI LVD within 72 hours of hospitalization for acute STEMI
  • Ejection fraction less than 35%
  • Express consent to participate in the study
  • Member or beneficiary of a social security scheme

Exclusion Criteria:

  • Patient with known carotid stenosis greater than 50%.
  • Patient with a history of AIS
  • Patient with AF
  • Patient with mechanical valve
  • Patient benefiting from a legal protection measure
  • Pregnant or breast-feeding women
  • History of cardiorespiratory arrest
  • Life expectancy of <6 months

Secondary exclusion criteria

  • Withdrawal of consent to participate in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 1
Device: Transcranial doppler (TCD)

A TCD with MES detection will be performed the day of the inclusion. Another TCD will be performed at 6 weeks of the inclusion. They will then receive telephone follow-up at one year, followed by a final visit two years after inclusion, blinded to the results of the TCD.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Demonstration of a correlation between the number of MES detected and the 2-year risk of AIS or the occurrence of a LVT at 6 weeks in patients with post-STEMI LVD.
Time Frame: To the enrollment period to 2-years of AIS or 6-weeks of a LVT
To the enrollment period to 2-years of AIS or 6-weeks of a LVT

Secondary Outcome Measures

Outcome Measure
Time Frame
Demonstration of a correlation between the number of MES detected and the treatment given (single anti-aggregation, double anti-aggregation, anti-coagulation) in patients suffering from LVD
Time Frame: To the enrollment period to 2-years of AIS or 6-weeks of a LVT
To the enrollment period to 2-years of AIS or 6-weeks of a LVT
Demonstration of a correlation between the variation in the number of MES detected and the modification of the treatment administered (single anti-aggregation, double anti-aggregation, anti-coagulation) in patients suffering from LVD
Time Frame: To the enrollment period to 2-years of AIS or 6-weeks of a LVT
To the enrollment period to 2-years of AIS or 6-weeks of a LVT
Demonstration of a correlation between the number of MES and the LVD rate according to the ACCF/AHA Heart Failure classification
Time Frame: At screening
At screening
Demonstration of a correlation between the number of MES detected and the risk of occurrence of an AIS at 2 years or LVT at 6 weeks in patients suffering from LVD, classified by subgroup of cardiac decompensation according to the ACCF/AHA Heart Failur
Time Frame: To the enrollment period to 2-years of AIS or 6-weeks of a LVT
To the enrollment period to 2-years of AIS or 6-weeks of a LVT
Creation of a large multicentric prospective follow-up database of patients suffering from LVD, whether symptomatic or not
Time Frame: To the enrollment period to the end of the follow-up, three years after
To the enrollment period to the end of the follow-up, three years after

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

CHC Montlegia

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

December 1, 2029

Study Registration Dates

First Submitted

November 6, 2026

First Submitted That Met QC Criteria

November 6, 2026

First Posted (Actual)

November 12, 2026

Study Record Updates

Last Update Posted (Actual)

November 12, 2026

Last Update Submitted That Met QC Criteria

November 6, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ML002

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe